ADAM17 and neoplasm: Yamamoto et al. described the generation of an ADAM17xCD3 bsAb in the BiTE format and conducted preclinical studies with regard to antigen selectivity and efficacy in killing PC tumor cells expressing ADAM17 in the presences of T cells [84].